A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

Also called NCT04576988

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 324 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04576988
  • EudraCT 2020-004142-11
Main results
  • Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension The New England journal of medicine, 2023-04-20 DOI, PubMed 36877098

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Serbia, South Korea, Spain, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04576988. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-25 (actual); primary completion 2022-08-26 (actual). Results posted on 2023-08-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
Condition
Pulmonary Arterial Hypertension
Intervention (Biological)
Sotatercept
Intervention (Drug)
Placebo
Intervention (Drug)
Background PAH Therapy
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (class: industry)

Record details

Record id
cardio:ct-nct04576988
Content hash
f684fb72643c132bb6442306875043701ee33f233b51bef012199e3a5bf85eef